Quture/TCLN Issues Shareholder Letter and Update
June 21 2012 - 8:31AM
Marketwired
Quture International, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN)
("Quture") today announced that the Chairman & CEO of Quture
has released a comprehensive shareholder letter to all known
shareholders of the company. The letter provides an update on
Quture business operations and a discussion of its future plans for
making the company a success in 2012 and beyond.
June 21, 2012
Dear Quture/TCLN Shareholders & Supporters:
I am pleased to take this opportunity to share with you the
basis for my belief that Quture, trading as TCLN, is well
positioned to market our products and services through several
subsidiaries to all potential customers in the health and health
care market. Quture is at a pivotal time of beginning marketing and
commercial sales of our QualOptima product, now programmed on the
InterSystems platform. We are starting with targeted "reference
hospitals" and look forward to reporting our progress. We believe
this will provide us with improved demonstration capabilities for
even more credible engagement with potential hospital
customers.
At the same time, you are beginning to see the various
subsidiary companies of Quture as they form: the North American
operations company Quture, Inc., the European operations subsidiary
Quture Euro, LLC and the Qx Health Exchange, LLC. I want to make
our strategy clear to investors about why we are positioning these
subsidiaries in Quture. The clinical data the QualOptima product
collects and analyzes into Quture's clinical knowledge has
extraordinary value to the total array of potential customers.
While we have explained the value of the product for internal
purposes of hospitals customers and their physicians, the same
information has unique and immense value to patients and to the
payers of their health care. Hospitals and their physicians can
coordinate personalized care around patients' specific risk factors
and outcomes. So the same clinical data can be formatted for a
variety of personalized health uses, applied through different
products and strategies in the various subsidiaries. HIPPA privacy
compliance is essential, but very manageable when done within
proscribed guidelines.
We have already emphasized the drivers for hospitals to license
the QualOptima product. But two other major forces are converging
beyond those: (1) the need for hospitals to market to their
patients, potential patients and to the payers for health care in
their region and (2) the transition to wellness and well care in a
proactive, patient-centered healthcare system where patients and
their employers take more responsibility in coordinating and
directing their health and care.
Hospitals are reported to spend more than $700 billion annually
on advertising. However, less than 20% of U.S. hospitals are guided
by an active strategy to market their brand, less than one-fifth of
hospitals nationwide. "Brand" equity is probably the single most
important tool in marketing, and hospitals increasingly need to
strengthen their brand. As patients assume more active roles in
healthcare decisions and health insurers focus more on results and
costs as the value equation for provider selection, brand equity is
becoming crucial in the highly competitive healthcare market.
My view is that forces in the health care market continue to
converge at the juncture where QualOptima fills a crucial void that
has inhibited hospitals and physicians from making clinical
data-driven decisions to improve care and reduce costs. Quture remains committed to our primary focus to
commercialize the QualOptima product. At the same time, Quture
is evaluating technologies that could provide us with significant
competitive and time-to-market advantages in the personalized
health area as well. In order to enter the personalized health
market earlier than the data from products timeline of our own
technology will allow, we are considering opportunities to acquire
assets or companies that provide supplementary clinical information
and interdisciplinary products that have already hit the market and
are generating revenues. In addition, we are also looking at the
possibility of purchasing or exclusively licensing personalized
performance and outcomes technology that could be productized
quickly. In order for us to move forward on either of these
options, we would need to gain a significant and sustainable
competitive advantage in addition to generating revenues.
In my mind, the way forward for Quture is clear. We will
continue to develop our unique and proprietary clinical performance
and outcomes enhancement technology. We are seeking channel
distribution options to augment our sales and marketing programs.
At the same time, we are exploring opportunities to quickly enter
the rapidly emerging personalized health market with products that
are based on a technology as compelling as our own. We intend to
build on the solid foundation of great technology with our
outstanding Application Partner InterSystems and with an
experienced management team. We continue to strive to build a
sustainable emerging growth company that provides lasting value to
our customers and to you, our shareholders.
Sincerely, Quture International, Inc. Landon Feazell Chairman
& Chief Executive Officer
ABOUT QUTURE INTERNATIONAL, INC.
(www.quture.com)
Quture International, Inc. is an emerging growth company
positioned to become the leading clinical knowledge company in the
world. The core competence of Quture is clinical performance
enhancement to achieve optimal patient outcomes. Quture's brand is
centered on the value proposition of trust, transparency and
independence. As the free enterprise solution to improving health
and health care while reducing costs, Quture is comprised of a
subsidiaries in North America and Europe for the operations of its
software technology solutions, plans for a "beyond data" consulting
and knowledge applications company, as well as plans for a
personalized, proactive, and predictive medicine company with a
virtual community of members. These subsidiaries will all be
affiliated with the Qx Medical Exchange, which the Company intends
to become the largest medical and health exchange in the world.
Quture International is a Nevada corporation currently trading
under the symbol TCLN.
This release contains forward-looking statements, including,
without limitation, statements concerning our business and possible
or assumed future results of operations. Our actual results could
differ materially from those anticipated in the forward-looking
statements for many reasons including: our ability to continue as a
going concern, adverse economic changes affecting markets we serve;
competition in our markets and industry segments; our timing and
the profitability of entering new markets; greater than expected
costs, customer acceptance of our products or difficulties related
to our integration of the businesses we may acquire; and other
risks and uncertainties as may be detailed from time to time in our
public announcements and SEC filings. Although we believe the
expectations reflected in the forward-looking statements are
reasonable, they relate only to events as of the date on which the
statements are made, and our future results, levels of activity,
performance or achievements may not meet these expectations. We do
not intend to update any of the forward-looking statements after
the date of this document to conform these statements to actual
results or to changes in our expectations, except as required by
law. There is no assurance that a definitive agreement will be
completed.
Contact: Mele Telitz Director of Communications
303-204-4486 mele@quture.com For Further Information
Contact: Constellation Asset Advisors, Inc. Jens Dalsgaard
President +1 (415) 524-8500